<DOC>
	<DOCNO>NCT01050634</DOCNO>
	<brief_summary>Quality life therapy Aromasin® ( exemestane ) accord IBCSG ( International Breast Cancer Study Group ) questionnaire . Change endometrium switch tamoxifen Aromasin® ( exemestane ) . Deeper knowledge Adverse Events routine administration .</brief_summary>
	<brief_title>Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer ( FAST )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Early Breast Cancer , postmenopausal , 23 yr adjuvant tamoxifen therapy .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Switch Tamoxifen</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Safety</keyword>
</DOC>